2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMORecruiting
The present study is aimed at identifying the specific routes of plitidepsin excretion and elimination following its administration to patients with advanced tumors. Also, the study design may allow the identification and quantification, if possible…